Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan
Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar
Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar
View: Text | PDF
Research Article Immunology Infectious disease

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan

  • Text
  • PDF
Abstract

A better understanding of the epitopes most relevant for antibody-mediated protection against tuberculosis (TB) remains a major knowledge gap. We have shown that human polyclonal IgG against the Mycobacterium tuberculosis (M. tuberculosis) surface glycan arabinomannan (AM) and related lipoarabinomannan (LAM) is protective against TB. To investigate the impact of AM epitope recognition and Fcγ receptor (FcγR) binding on antibody functions against M. tuberculosis, we isolated a high-affinity human monoclonal antibody (mAb; P1AM25) against AM and showed its binding to oligosaccharide (OS) motifs we previously found to be associated with in vitro functions of human polyclonal anti-AM IgG. Human IgG1 P1AM25, but not 2 other high-affinity human IgG1 anti-AM mAbs reactive with different AM OS motifs, enhanced M. tuberculosis phagocytosis by macrophages and reduced intracellular growth in an FcγR-dependent manner. P1AM25 in murine IgG2a, but neither murine IgG1 nor a non–FcγR-binding IgG, given intraperitoneally prior to and after aerosolized M. tuberculosis infection, was protective in C57BL/6 mice. Moreover, we demonstrated the protective efficacy of human IgG1 P1AM25 in passive transfer with M. tuberculosis–infected FcγR-humanized mice. These data enhance our knowledge of the important interplay between both antibody epitope specificity and Fc effector functions in the defense against M. tuberculosis and could inform development of vaccines against TB.

Authors

Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar

×

Figure 2

Human mAb P1AM25 shows strong binding to AM/LAM and M. tuberculosis strains.

Options: View larger image (or click on image) Download as PowerPoint
Human mAb P1AM25 shows strong binding to AM/LAM and M. tuberculosis stra...
(A) Binding of P1AM25 (red) in comparison with T1AM09 (blue) and L1AM04 (green) to M. tuberculosis capsular AM and (B) LAM of H37Rv and CDC1551 determined by ELISA (AM and LAM coated at 10 μg/mL). Binding of anti-AM mAbs to whole bacteria of (C) avirulent H37Ra and virulent (D) H37Rv and (G) Erdman M. tuberculosis lab strains, and clinical M. tuberculosis strains (E) CDC1551 and (F) HN878 (Beijing), assessed by ELISA. Bacteria were grown stationary and without detergent to preserve the capsule. All ELISA data are representative of 2 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts